|drug1685||vv-ECMO only (no cytokine adsorption) Wiki||0.71|
|drug1684||vv-ECMO + cytokine adsorption (Cytosorb adsorber) Wiki||0.71|
|drug1453||Usual Care Wiki||0.50|
|D045169||Severe Acute Respiratory Syndrome NIH||0.06|
|D018352||Coronavirus Infections NIH||0.05|
There is one clinical trial.
This study aims to determine if provider-recommended guidance on supine (on back) vs. prone (on stomach) positioning of patients testing positive for COVID-19 requiring supplemental oxygen, but not yet mechanically ventilated, improves outcomes in the inpatient setting. This study will be performed as a pragmatic clinical trial.
Description: The highest level of support on the 5th day after enrollment according to the following scale adjusted for patient status at enrollment according to the same scale and ranked by mean FIO2 within each category, as appropriate. Death ECMO Mechanical ventilation (ranked by mean FIO2) Non-invasive ventilation such as BiPAP (ranked by mean FIO2) High flow nasal cannula, e.g. Optiflow, Vapotherm or other similar device (titrated by FiO2%) (ranked by mean FIO2) Standard nasal cannula (titrated by L/min up to 15 L/min) or face mask (ranked by mean FIO2) Room airMeasure: Modified WHO Ordinal Scale Time: 5 days post-randomization
Description: Mean FIO2 over the first 5 daysMeasure: Mean FIO2 Time: First 5 days post-randomization